TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Solasia Pharma KK ( (JP:4597) ) has shared an update.
Solasia Pharma K.K. has announced an impairment loss for fiscal year 2024 due to challenges in securing a licensing agreement for DARVIAS® in China and limited market penetration for its current indication of peripheral T-cell lymphoma. This has resulted in a revaluation of intangible assets and a recorded impairment loss of 959 million yen, affecting their consolidated earnings, which fell short of previous forecasts.
More about Solasia Pharma KK
Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology-focused products. The company is engaged in out-licensing activities, particularly in China, and is advancing preclinical development for its product DARVIAS® to expand its indications.
YTD Price Performance: 21.05%
Average Trading Volume: 304
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €53.48M
Learn more about 4597 stock on TipRanks’ Stock Analysis page.